Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Penumbra Inc PEN

Healthcare Medical Devices
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.


NYSE:PEN - Post by User

Penumbra Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(433)
•••
Post by AwareInvestoron Dec 30, 2020 10:51am
124 Views
Post# 32196910

The Emperor’s Decree: Marcus Aurelius Has Some Thoughts Abou

The Emperor’s Decree: Marcus Aurelius Has Some Thoughts Abou
Yesterday, the coalition of activist short sellers who have been nipping at the ankles of medical devices company Penumbra got some help from Marcus Aurelius Value, who did the legwork to connect various individuals involved with Penumbra and Penumbra’s clinical trials to rival thrombectomy device maker ev3, which was fined in 2018 for encouraging off-label use of its Onyx liquid embolization system.
 
Ev3 and parent company Covidian, also fined as part of the 2018 USDOJ action, are presently properties of Medtronic. The fund has raised legitimate questions about Penumbra’s clinical trials process, and suggested that there is a pattern of skid-greasing at Penumbra that is indicative of institutional rot.

https://thedeepdive.ca/the-emperors-decree-marcus-aurelius-has-some-thoughts-about-penumbra/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities